FLX-475 is under clinical development by RAPT Therapeutics and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FLX-475’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FLX-475 is under development for the treatment of metastatic gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, triple negative breast cancer, urothelial carcinoma, gastric cancer, non-Hodgkin lymphoma, esophageal carcinoma, cervical cancer, classical Hodgkin lymphoma, hematological malignancies and solid tumors. The drug candidate is administered orally. It act by targeting chemokine receptor type 4 (CCR4).
It was also under development for the treatment of colorectal adenocarcinoma and ovarian cancer, advanced melanoma.
RAPT Therapeutics overview
RAPT Therapeutics operates as an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compounds such as FLX475 which blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate cancer. The company has advanced into the clinic with a dual-inhibitor drug that targets FLT3 and CDK4 and 6 for the treatment of cancer. RAPT Therapeutics is headquartered in South San Francisco, California, the US
For a complete picture of FLX-475’s drug-specific PTSR and LoA scores, buy the report here.